Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00347009 |
This 36-month open-label study of adefovir dipivoxil investigates the clinical benefits of the therapy in chronic hepatitis B patients with advanced fibrosis or cirrhosis confirmed with biopsy. Primary endpoint is histological improvement defined as a decrease of Ishak Fibrosis Score by one point or more from baseline at Month 36 of adefovir dipivoxil treatment. Approximately 150 patients will be recruited in study centres in the Asia Pacific area. The patients are offered 36 months of open label adefovir dipivoxil treatment, with assessments every three months, after which there is a 6-month post study treatment follow-up prior to study completion. After the 36 months of study treatment, it is likely that the patient will benefit from continued treatment with adefovir dipivoxil. If this is the case in the investigators clinical judgement, the investigator should ensure that a routine prescription is available in a timely manner, and that no unnecessary interruption in treatment occurs.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B Fibrosis Cirrhosis |
Drug: adefovir dipivoxil |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | An Open Label Study of Adefovir Dipivoxil for the Treatment of Patients With Chronic Hepatitis B Related Advanced Fibrosis or Cirrhosis. |
Estimated Enrollment: | 150 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any of the following laboratory parameter within 4 weeks prior to study entry: -Haemoglobin <8.0 g/dL, -Absolute neutrophil count (ANC) < 1.5 x 10^9/L, -Platelet count ≤50 x 10^9/L, -Pancreatic amylase and/or lipase >2 x ULN
Hong Kong | |
GSK Investigational Site | |
Pokfulam, Hong Kong | |
Korea, Republic of | |
GSK Investigational Site | |
Sungnam-City, Korea, Republic of, 463-712 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 135-710 | |
GSK Investigational Site | |
Daegu, Korea, Republic of, 700-712 | |
GSK Investigational Site | |
Pusan, Korea, Republic of, 602-739 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 137-701 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 120-752 | |
Singapore | |
GSK Investigational Site | |
Singapore, Singapore, 169608 | |
Taiwan | |
GSK Investigational Site | |
Taipei, Taiwan, 114 | |
GSK Investigational Site | |
Kaohsiung, Taiwan, 833 | |
GSK Investigational Site | |
Taipei, Taiwan, 100 | |
Vietnam | |
GSK Investigational Site | |
Ho Chi Minh City, Vietnam |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | ADF104070 |
Study First Received: | June 30, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00347009 |
Health Authority: | Taiwan: Department of Health |
Chronic Hepatitis B Cirrhosis Advanced Fibrosis Adefovir Dipivoxil |
Liver Diseases Hepatitis, Chronic Fibrosis Hepatitis, Viral, Human Liver Cirrhosis Hepatitis Virus Diseases |
Digestive System Diseases Hepatitis B, Chronic Hepatitis B DNA Virus Infections Adefovir dipivoxil Adefovir |
Anti-Infective Agents Pathologic Processes Anti-Retroviral Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Enzyme Inhibitors |
Antiviral Agents Hepadnaviridae Infections Nucleic Acid Synthesis Inhibitors Pharmacologic Actions Reverse Transcriptase Inhibitors |